1. Home
  2. MGTX vs SLBT Comparison

MGTX vs SLBT Comparison

Compare MGTX & SLBT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo MeiraGTx Holdings plc

MGTX

MeiraGTx Holdings plc

BUY

Current Price

$10.89

Market Cap

1.0B

Sector

Health Care

ML Signal

BUY

Logo SL Science Holding Limited Ordinary Shares

SLBT

SL Science Holding Limited Ordinary Shares

N/A

Current Price

$1.57

Market Cap

942.1M

Sector

N/A

ML Signal

N/A

Company Overview

Basic Information
Metric
MGTX
SLBT
Founded
2015
N/A
Country
United States
Taiwan
Employees
N/A
N/A
Industry
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.0B
942.1M
IPO Year
2018
2025

Fundamental Metrics

Financial Performance
Metric
MGTX
SLBT
Price
$10.89
$1.57
Analyst Decision
Buy
Analyst Count
8
0
Target Price
★ $27.75
N/A
AVG Volume (30 Days)
★ 932.9K
101.3K
Earning Date
11-12-2026
N/A
Dividend Yield
N/A
N/A
EPS Growth
★ 33.02
N/A
EPS
★ 1.30
N/A
Revenue
★ $81,391,000.00
N/A
Revenue This Year
$314.19
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
$8.40
★ N/A
Revenue Growth
★ 144.57
N/A
52 Week Low
$6.62
$1.42
52 Week High
$15.35
$6.25

Technical Indicators

Market Signals
Indicator
MGTX
SLBT
Relative Strength Index (RSI) 31.37 33.81
Support Level $8.84 $1.42
Resistance Level $11.85 $3.36
Average True Range (ATR) 0.58 0.17
MACD -0.18 0.01
Stochastic Oscillator 13.29 21.74

Price Performance

Historical Comparison
MGTX
SLBT

About MGTX MeiraGTx Holdings plc

MeiraGTx Holdings PLC is a vertically integrated, clinical-stage genetic medicines company focused on developing targeted therapies for diseases with high unmet need, including radiation-induced xerostomia, Parkinson's disease, and AIPL1-associated retinal dystrophy. The company's pipeline is supported by end-to-end in-house manufacturing capabilities, including GMP viral vector production, plasmid manufacturing, and quality control, enabling development from IND to commercial supply. It also utilizes proprietary platforms in viral vector optimization and riboswitch-based gene regulation to enhance efficacy and reduce dosage. The company operates in the United States, the United Kingdom, and the European Union.

About SLBT SL Science Holding Limited Ordinary Shares

SL Science Holding Ltd is a biomedical company specialized in developing cellular and gene therapies advancing regenerative medicine and cancer treatment. It utilizes immune stem cells to target cancer and bovine-derived milk exosomes to regenerate damaged tissues, thus potentially offering expansive medical applications for its products. With proprietary technologies such as Armed-T and Gamma Delta T cells, as well as exosome applications in skincare and cancer recovery. It operates in three segments namely Exosome products, CD-19 Armed-T products, and GDT cell therapy products. It derives revenue from Exosome products segment.

Share on Social Networks: